First European Sale of APAS Independence
We are pleased to announce the first sale of an APAS® Independence instrument in the European Union to Labor Dr Wisplinghoff
continue readingLBT Innovations @ ExchangeSA
Today our Managing Director and CEO Brent Barnes presented at the ExchangeSA 2019 listed companies conference in Adelaide
continue readingMRSA Analysis Module CE Mark Registration
We are pleased to announce that the Declaration of Conformity for the APAS® Independence MRSA analysis module has been completed.
continue readingFinance News Network Interview with Brent Barnes
Brent Barnes, talks FY19 results and outlook and the adoption of our culture plate reading device APAS,, the sales process and regulatory approval.
continue readingASX Small and Mid-Cap Conference 2019
LBT's CEO and Managing Director Brent Barnes presenting at the ASX Small and Mid-Cap Conference in Sydney on the 5th of September 2019
continue readingProactive Investors Interview with Brent Barnes
Brent Barnes updates Proactive Investors on developments to forge ahead with product sales of its unique APAS Independence technology.Â
continue readingLBT Presentation, FNN Investor Event
Our CEO presents on LBT's automated plate reading device for use in laboratories, regulatory clearance in the US and the size of the market opportunity.
continue readingBioshares Analyst Report
LBT Innovations is resetting expectations with investors regarding the sale process for its automated plate processing instrument, called APAS Independence. Read the full report here.
continue readingMRSA Analysis Module – Clinical Study Commenced
We are pleased to announce that we have commenced a clinical study to validate clinical performance of APAS Independence’s automatic analysis of MRSA.
continue readingBreaking Into The US Market. What Does It Really Take?Â
Our VP of Global Business Development Peter Bradley recently presented at the ANDHealth Digital Health Summit in Melbourne
continue reading
